Related Experiment Video
Updated: Apr 1, 2026
Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion
Published on: August 29, 2018
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells
S G M Piccirillo1, B A Reynolds, N Zanetti
1Department of Biotechnology and Biosciences, University of Milan-Bicocca, 20126 Milan, Italy.
Abstract:
Transformed, oncogenic precursors, possessing both defining neural-stem-cell properties and the ability to initiate intracerebral tumours, have been identified in human brain cancers. Here we report that bone morphogenetic proteins (BMPs), amongst which BMP4 elicits the strongest effect, trigger a significant reduction in the stem-like, tumour-initiating precursors of human glioblastomas (GBMs). Transient in vitro exposure to BMP4 abolishes the capacity of transplanted GBM cells to establish intracerebral GBMs. Most importantly, in vivo delivery of BMP4 effectively blocks the tumour growth and associated mortality that occur in 100% of mice after intracerebral grafting of human GBM cells. We demonstrate that BMPs activate their cognate receptors (BMPRs) and trigger the Smad signalling cascade in cells isolated from human glioblastomas (GBMs). This is followed by a reduction in proliferation, and increased expression of markers of neural differentiation, with no effect on cell viability. The concomitant reduction in clonogenic ability, in the size of the CD133+ population and in the growth kinetics of GBM cells indicates that BMP4 reduces the tumour-initiating cell pool of GBMs. These findings show that the BMP-BMPR signalling system--which controls the activity of normal brain stem cells--may also act as a key inhibitory regulator of tumour-initiating, stem-like cells from GBMs and the results also identify BMP4 as a novel, non-cytotoxic therapeutic effector, which may be used to prevent growth and recurrence of GBMs in humans.
Insights
Bone morphogenetic proteins (BMPs), particularly BMP4, significantly reduce the stem-like cells that initiate human glioblastomas (GBMs). This discovery offers a novel, non-cytotoxic therapeutic strategy for preventing GBM growth and recurrence.
Area of Science:
- Neuro-oncology
- Stem Cell Biology
- Molecular Signaling
Background:
- Human brain cancers contain oncogenic precursors with neural stem cell properties capable of initiating tumors.
- Glioblastomas (GBMs) are aggressive brain tumors often driven by a subpopulation of stem-like, tumor-initiating cells.
Purpose of the Study:
- To investigate the role of bone morphogenetic proteins (BMPs) in regulating the stem-like, tumor-initiating cells of human glioblastomas.
- To evaluate BMP4 as a potential therapeutic agent for GBM treatment.
Main Methods:
- In vitro and in vivo experiments using human glioblastoma cells and mouse models.
- Analysis of BMP-BMPR signaling pathway activation (Smad cascade).
- Assessment of cell proliferation, differentiation markers, clonogenic ability, and CD133+ population.
Main Results:
- BMP4 significantly reduced the stem-like, tumor-initiating capacity of GBM cells in vitro.
- In vivo delivery of BMP4 effectively inhibited GBM tumor growth and mortality in mice.
- BMPs activated the Smad signaling cascade, leading to reduced proliferation and increased neural differentiation markers without affecting cell viability.
Conclusions:
- The BMP-BMPR signaling system acts as an inhibitory regulator of tumor-initiating stem-like cells in GBMs.
- BMP4 is identified as a novel, non-cytotoxic therapeutic effector for preventing GBM growth and recurrence.
